Patents Assigned to Institute for Cancer Research
  • Ocular prosthesis with display device
    Patent number: 10820986
    Abstract: An ocular prosthesis includes a display device visible at an anterior portion of the ocular prosthesis. The display device is configured to present a changeable image that represents a natural appearance and movement for a visible portion of an eyeball of a subject. A system includes, besides the ocular prosthesis, an implant marker configured to move with an orbital implant disposed in an eye socket of a subject. A method includes determining a change in orientation of an orbital implant in a subject and determining an update to a natural appearance for a visible portion of an eyeball for the subject based on the change in orientation of the orbital implant. The method also includes rendering an update to an image of the natural appearance for a display device disposed in an ocular prosthesis configured to be inserted in the subject anterior to the orbital implant.
    Type: Grant
    Filed: January 8, 2014
    Date of Patent: November 3, 2020
    Assignee: Sloan Kettering Institute for Cancer Research
    Inventors: David Abramson, George C. Bohle, III, Paul Frisch, Brian P. Marr, Paul Booth, Philip C. Black, Alan B. Katze, James G. Moore
  • METHOD FOR EXPANSION OF LYMPHOCYTES
    Publication number: 20200338125
    Abstract: The invention relates to a method for expanding antigen-specific lymphocytes by culturing samples from a subject containing lymphocytes or lymphocytes derived from the sample in the presence of one or more peptides comprising antigens and/or in the presence of an antigen presenting cell presenting antigens. Also disclosed is the use of such method for improving personalized immunotherapy (e.g., tumor immunotherapy).
    Type: Application
    Filed: November 6, 2018
    Publication date: October 29, 2020
    Applicant: LUDWIG INSTITUTE FOR CANCER RESEARCH LTD
    Inventors: Sara BOBISSE, Alexandre HARARI, George COUKOS
  • INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF
    Publication number: 20200331921
    Abstract: The present application relates to compounds of Formula I (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.
    Type: Application
    Filed: February 6, 2019
    Publication date: October 22, 2020
    Applicant: Ontario Institute for Cancer Research (OICR)
    Inventors: Rima Al-awar, Methvin Isaac, Anh My Chau, Ahmed Mamai, Lain Watson, Gennady Poda, Pandiaraju Subramanian, Brian Wilson, David Uehling, Michael Prakesch, Babu Joseph, Justin-Alexander Morin
  • Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer
    Patent number: 10807974
    Abstract: Provided are compounds of the Formula (I), or a pharmaceutically acceptable salt thereof: wherein W, X, Y, Z, x, R1, R2, R3, x and n are defined in the specification. The compounds are inhibitors of lysyl oxidase (LOX) and lysyl oxidase-like (LOXL) family members (LOXL1, LOXL2, LOXL3, LOXL4) and are useful in therapy, particularly in the treatment of cancer. Also disclosed are LOX inhibitors for use in the treatment of a cancer associated with EGFR and biomarkers that predict responsiveness to a LOX inhibitor.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: October 20, 2020
    Assignee: The Institute of Cancer Research: Royal Cancer Hospital
    Inventors: Caroline Springer, Richard Marais, Dan Niculescu-Duvaz, Leo Leung, Deborah Smithen, Cedric Callens, Haoran Tang
  • NOVEL QUINOLONE COMPOUNDS AS INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND/OR AS BCL6 DEGRADERS
    Publication number: 20200325119
    Abstract: The present application relates to compounds of Formula I or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB and/or by degrading BCL6, such as cancer.
    Type: Application
    Filed: December 20, 2018
    Publication date: October 15, 2020
    Applicant: Ontario Institute for Cancer Research (OICR)
    Inventors: Methvin Isaac, Anh My Chau
  • Anti-GITR antibodies and methods of use thereof
    Patent number: 10800849
    Abstract: The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: October 13, 2020
    Assignees: Agenus Inc., Memorial Sloan-Kettering Cancer Center, Ludwig Institute for Cancer Research Ltd.
    Inventors: Ana M. Gonzalez, Nicholas S. Wilson, Dennis J. Underwood, Volker Seibert, Olivier Léger, Marc Van Dijk, Roberta Zappasodi, Taha Merghoub, Jedd David Wolchok, David Schaer, Gerd Ritter, Takemasa Tsuji
  • Products and methods for treatment of familial amyotrophic lateral sclerosis
    Patent number: 10793861
    Abstract: The present invention relates to RNA-based methods for inhibiting the expression of the superoxide dismutase 1 (SOD-1) gene. Recombinant adeno-associated viruses of the invention deliver DNAs encoding RNAs that knock down the expression of SOD-1. The methods have application in the treatment of amyotrophic lateral sclerosis.
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: October 6, 2020
    Assignees: RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL, LUDWIG INSTITUTE FOR CANCER RESEARCH
    Inventors: Brian K. Kaspar, Kevin Foust, Don W. Cleveland
  • NOVEL DEUTERATED COMPOUNDS AS INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND/OR AS BCL6 DEGRADERS
    Publication number: 20200308147
    Abstract: The present application relates to compounds of Formula I (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB and/or by degrading BCL6, such as cancer.
    Type: Application
    Filed: December 21, 2018
    Publication date: October 1, 2020
    Applicant: Ontario Institute for Cancer Research (OICR)
    Inventors: Methvin Isaac, Anh My Chau, Ahmed Mamai
  • iNKT cell modulators and methods of using the same
    Patent number: 10765648
    Abstract: Disclosed herein are ?-galactosylceramide (?-GalCer) analogs and compositions thereof, methods of activating invariant Natural Killer T (iNKT) cells using said analogs, methods of treating diseases by activating iNKT cells using said analogs, and combination therapy of said analogs.
    Type: Grant
    Filed: April 17, 2019
    Date of Patent: September 8, 2020
    Assignee: LUDWIG INSTITUTE FOR CANCER RESEARCH
    Inventors: Vincenzo Cerundolo, Gurdyal S. Besra, Liam R. Cox
  • Crystalline forms of an androgen receptor modulator
    Patent number: 10766875
    Abstract: Described herein are amorphous and crystalline forms of the androgen receptor modulator 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide. Also described are pharmaceutical compositions suitable for administration to a mammal that include the androgen receptor modulator, and methods of using the androgen receptor modulator, alone and in combination with other compounds, for treating diseases or conditions that are associated with androgen receptor activity.
    Type: Grant
    Filed: December 11, 2019
    Date of Patent: September 8, 2020
    Assignees: Aragon Pharmaceuticals, Inc., Sloan-Kettering Institute for Cancer Research
    Inventors: Anna Dihas, Mark R. Herbert, Ouathek Ouerfelli, Nicholas D. Smith
  • PLK4 inhibitors
    Patent number: 10752612
    Abstract: Provided herein, inter alia, are compounds and methods for inhibiting PLK4 and for treating cancer in a subject in need thereof.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: August 25, 2020
    Assignee: LUDWIG INSTITUTE FOR CANCER RESEARCH LTD
    Inventors: Timothy Gahman, Andrew Shiau
  • Biopsy-driven genomic signature for prostate cancer prognosis
    Patent number: 10745760
    Abstract: There is provided herein, systems, devices and methods for determining a risk of recurrence of cancer following a cancer therapy of a patient by determining genomic instability of a tumour. There is further provided systems, devices and methods for categorizing a patient into a prognostic cancer sub-group by using copy number alterations.
    Type: Grant
    Filed: January 16, 2015
    Date of Patent: August 18, 2020
    Assignees: University Health Network, Ontario Institute for Cancer Research
    Inventors: Paul Boutros, Robert G. Bristow, Emilie Lalonde
  • Dual inhibition of CDK and HSP90 destabilize HIF1alpha and synergistically induces cancer cell death
    Patent number: 10729692
    Abstract: The present disclosure provides pharmaceutical compositions including a CDK inhibitor and an HSP90 inhibitor, as well as methods of treating cancer or a tumor in a subject by administering a CDK inhibitor and an HSP90 inhibitor to the subject.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: August 4, 2020
    Assignee: Institute For Cancer Research
    Inventors: Shuai Zhao, Wafik S. El-Deiry
  • PROGNOSTIC AND TREATMENT RESPONSE PREDICTIVE METHOD
    Publication number: 20200239968
    Abstract: The present invention provides a method for predicting the treatment response of a human gastroesophageal cancer patient, the method comprising: a) measuring the gene expression of at least 3 of the following genes: CDH1, CDK6, COX2, ELOVL5, GATA4, EGFR, TBCEL, FGF7, CDH17, FNBP1, PIP5K1B, TWIST, CD44, MET, CEACAM1, TOX3, GLIPR2, GSTP1, RON, TMEM136, MYB, BRCA2, FGF1, POU5F1, EPR, DPYD, ABL2 and SH3RF1 in a sample obtained from the gastroesophageal tumour of the patient to obtain a sample gene expression profile of at least said genes; and b) making a prediction of the treatment response and/or prognosis of the patient based on the sample gene expression profile. Also provided are related computer-implemented methods and methods of treatment of gastroesophageal cancer.
    Type: Application
    Filed: October 12, 2018
    Publication date: July 30, 2020
    Applicants: The Institute of Cancer Research: Royal Cancer Hospital, The Royal Marsden NHS Foundation Trust, National University of Singapore
    Inventors: Elizabeth Smyth, Anguraj Sadanandam, Gift Nyamundanda, David Cunningham, Boon Ooi Patrick Tan
  • TGF-?3 specific antibodies and methods and uses thereof
    Patent number: 10723793
    Abstract: Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 3 (TGF-?3) are provided, particularly recognizing human and mouse TGF-?3, particularly antibodies and fragments that do not recognize or bind TGF-?1 or TGF-?2. Particular antibodies are provided which specifically recognize and neutralize TGF-?3. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-?3, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-?3 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: July 28, 2020
    Assignee: Ludwig Institute for Cancer Research, Ltd.
    Inventors: Jacques Van Snick, Catherine Uyttenhove
  • Methods for enriching gene-targeted cells
    Patent number: 10724051
    Abstract: A gene of interest and the gene encoding hypoxanthine-aminopterin-thymidine (HPRT) can be co-targeted for Casp9 nuclease-mediated editing or alteration in a cell. Based on whether the HPRT gene is altered to encode a non-functional protein, or is not so-altered, the co-targeted cells can be selected and counter-selected. HPRT co-targeting can be used to sequentially disrupt as many genes of interest as cell viability permits.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: July 28, 2020
    Assignee: Institute For Cancer Research
    Inventors: Hong Yan, Shuren Liao
  • Methods for treating GI syndrome and graft versus host disease
    Patent number: 10722577
    Abstract: It has been discovered that administering therapeutically effective amounts of an antibiotic that kills Gram-negative bacteria, together with an anti-ceramide antibody or anti-ceramide mimetic, treats and prevents an array of diseases mediated by cytolytic T lymphocyte (CTL)-induced killing and/or by damage to endothelial microvasculature, including Radiation GI syndrome, GvHD disease, inflammatory diseases and autoimmune diseases.
    Type: Grant
    Filed: May 28, 2013
    Date of Patent: July 28, 2020
    Assignee: Sloan Kettering Institute for Cancer Research
    Inventors: Jimmy Andrew Rotolo, Richard N. Kolesnick
  • Systems and methods for treating patients having a genetic predisposition to develop prostate cancer
    Patent number: 10724100
    Abstract: Systems and methods for mitigating prostate cancer development are provided. Peripheral blood cells may be evaluated for the presence or quantity of gamma-H2AX foci, and/or for gene alterations encoding a protein with impaired or lack of function, for example, because the encoded protein is truncated, and correlating with prostate cancer development. Such nucleic acids may encode proteins from or peripheral to the DNA damage repair pathway and/or androgen receptor signaling pathway, or that are otherwise correlated with prostate cancer development. Such genes include one or more of AKR1C1, PALB2, APTX, BLM, BRCA1, CTBP1, DDB2, FANCA, FANCL, MBD5, MSH3, NEIL3, RAD51D, RAD54L2, SP1, TP53BP1, UBE2D3, UBE2V2, NRIP1, EFCAB6, CRISP3, PAPSS2, ATP6V0A2, ALG13, MGAT2, B3GAT3, DOLK, FLT3, ASXL1, KDR, or NOTCH2.
    Type: Grant
    Filed: September 16, 2015
    Date of Patent: July 28, 2020
    Assignee: Institute For Cancer Research
    Inventors: Sanjeevani Arora, Greg Enders, Erica Golemis, Emmanuelle Nicolas, Ilya Serebriiskii
  • Small-molecule HSP90 inhibitors
    Patent number: 10676476
    Abstract: Purine scaffold Hsp90 inhibitors are useful in therapeutic applications and as radioimaging ligands.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: June 9, 2020
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Gabriela Chiosis, Huazhong He, Laura Llauger-Bufi, Joungnam Kim, Steven M. Larson, Peter Smith-Jones
  • Methods and compositions for modulation of blood-neural barrier
    Patent number: 10676527
    Abstract: Methods and compositions for modulating blood-neural barrier (BNB) for the treatment of CNS conditions such as edema, and for increased drug delivery efficacy across the BNB. The present invention further relates to improved tPA treatment of ischemic cerebrovascular and related diseases in combination with antagonism of the PDGF signaling pathway. The inventive method and composition is particularly suitable for conjunctive therapy of ischemic stroke using tPA and an anti-PDGF-C antagonist or an anti-PDGFR-? antagonist.
    Type: Grant
    Filed: February 12, 2018
    Date of Patent: June 9, 2020
    Assignees: Ludwig Institute for Cancer Research Ltd., The Regents of the University of Michigan, University of Maryland, Baltimore
    Inventors: Ulf Eriksson, Linda Fredriksson, Daniel Lawrence, Enming Su, Manuel Yepes, Dudley Strickland